HTA Consulting examined the availability and waiting time for reimbursed drugs with orphan status registered by EMA in Poland in 2004-2018 (18/04/2018).Currently in Poland (as of 18/04/2018), 21 innovative medicines with orphan status (out of 104) registered in EMA are reimbursed. 8 of them were
HTA Consulting assessed the availability of orphan drugs with high unmet need (non-oncological drugs, the only one with orphan status registered after 2012 by EMA). Results from 32 countries were obtained - all EU and EFTA countries were analyzed except Cyprus (as of 10/04/2018)Average number
During the Congress of the Polish Diabetological Association taking place on 24-26 May 2018, a poster will be presented: "Continuous subcutaneous insulin infusion versus multiple daily injections in pregnant women with type 1 diabetes mellitus — a systematic review and meta-analysis of randomised controlled trials
We are pleased to inform you that the article: "Continuous subcutaneous insulin infusion versus multiple daily injections in pregnant women with type 1 diabetes mellitus — a systematic review and meta-analysis of randomised controlled trials and observational studies" co-authored by Przemysław Ryś, the vice president of
A full program of workshops taking place as part of the upcoming 26th International Student Medical Conference is now available here. HTA Consulting will lead two sessions:The reimbursement process in Poland. Why are some medicines reimbursed and others not? Magdalena Władysiuk Unusual research models. The advanced
As part of the upcoming 26th International Student Medical Conference, which will be held in Krakow on April 19-21, HTA Consulting became a sponsor of the awards and took patronage over two sessions: Public Health and Pharmacy. The company will also fund additional prizes for
Rzeczpospolita lately published the article Drug reimbursement: The European Commission wants common rules for the entire EU, in which Magdalena Władysiuk, Vice-president of HTA Consulting, gave her opinion on the draft regulation on the health technology assessment and amending the Directive 2011/24/EU.The full text of the